{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:44Z","timestamp":1792898924466,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijid.2019.02.013","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T17:10:17Z","timestamp":1550596217000},"page":"210-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["Multicenter clinical experience of real life Dalbavancin use in gram-positive infections"],"prefix":"10.1016","volume":"81","author":[{"given":"S.","family":"Wunsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Prattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Janata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bellmann-Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-1837","authenticated-orcid":false,"given":"I.","family":"Zollner-Schwetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"December","key":"10.1016\/j.ijid.2019.02.013_bib0005","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"issue":"January (2)","key":"10.1016\/j.ijid.2019.02.013_bib0010","first-page":"1","article-title":"The role of dalbavancin in skin and soft tissue infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"August (4)","key":"10.1016\/j.ijid.2019.02.013_bib0015","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"issue":"November","key":"10.1016\/j.ijid.2019.02.013_bib0020","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","author":"Bouza","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"March (5)","key":"10.1016\/j.ijid.2019.02.013_bib0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: a novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"April (4)","key":"10.1016\/j.ijid.2019.02.013_bib0030","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"March (5)","key":"10.1016\/j.ijid.2019.02.013_bib0035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"February (2)","key":"10.1016\/j.ijid.2019.02.013_bib0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf"},{"issue":"March (3)","key":"10.1016\/j.ijid.2019.02.013_bib0045","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"June","key":"10.1016\/j.ijid.2019.02.013_bib0050","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/TCRM.S86330","article-title":"Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)","volume":"12","author":"Leuthner","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"January (1)","key":"10.1016\/j.ijid.2019.02.013_bib0055","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"July (11)","key":"10.1016\/j.ijid.2019.02.013_bib0060","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-015-0430-x","article-title":"Dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"November (10)","key":"10.1016\/j.ijid.2019.02.013_bib0065","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"April","key":"10.1016\/j.ijid.2019.02.013_bib0070","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219300773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219300773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T04:14:37Z","timestamp":1606536877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971219300773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":14,"alternative-id":["S1201971219300773"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.02.013","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}